We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Progress Pediatric Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01328288
Recruitment Status : Completed
First Posted : April 4, 2011
Last Update Posted : February 22, 2016
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to study the HIV disease progression in HIV-infected Thai children.

Condition or disease Intervention/treatment
HIV Depression Drug: standard ART according to the Thai Ministry of Public Health national guidelines

Detailed Description:
This is a multicenter, observational cohort study. HIV-infected children from 5 institutions are followed to assess HIV disease progression: 1. Bamrasnaradura infectious disease institute,2. Faculty of Medicine Siriraj Hospital, Mahidol University, 3. Chiangrai Prachanukroh Hospital, 4. Sanpatong Hospital and 5. HIV-NAT, Thai Red Cross AIDS Research Center.

Study Design

Study Type : Observational
Actual Enrollment : 840 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Thai Pediatric HIV Disease Progression: An Observational Database
Study Start Date : January 2009
Primary Completion Date : September 2015
Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
1
long-term follow-up of HIV-infected children
Drug: standard ART according to the Thai Ministry of Public Health national guidelines
Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.


Outcome Measures

Primary Outcome Measures :
  1. HIV related adverse events [ Time Frame: 1 year ]
    time to HIV related adverse events


Secondary Outcome Measures :
  1. Immunological failure [ Time Frame: 1 year ]
    time to immunological failure

  2. virological failure [ Time Frame: 1 year ]
    time to virological failure

  3. quality of life [ Time Frame: 1 year ]
    time to change of quality of life

  4. depression [ Time Frame: 1 year ]
    when patient develops depression

  5. genotypic resistance [ Time Frame: 1 year ]
    time to genotypic resistance


Biospecimen Retention:   Samples With DNA
serum

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
long-term follow-up of HIV-infected children from: 1. Bamrasnaradura infectious disease institute, 2. Faculty of Medicine Siriraj Hospital, Mahidol University, 3. Chiangrai Prachanukroh Hospital, Chiang Rai, 4. Sanpatong Hospital, Chiang Mai, and 5. HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok
Criteria

Inclusion Criteria:

  1. age < 18 years old
  2. Have confirmed HIV infection (ELISA,HIV-DNA PCR,HIV-RNA PCR)
  3. Signed consent form

Exclusion Criteria:

  1. Hospitalization
  2. Emergency case
  3. Incomplete Medical Record
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01328288


Locations
Thailand
Sanpatong Hospital
Sanpathong, Chiang Mai, Thailand
HIV-NAT, Thai Red Cross AIDS Research Centre
Bangkok, Thailand, 10330
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand
Chiangrai Prachanukroh Hospital
Chiang Rai, Thailand
Bamrasnaradura infectious disease institute
Nonthaburi, Thailand, 11000
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Bamrasnaradura Infectious Diseases Institute
Mahidol University
Chiangrai Prachanukroh Hospital
Sanpatong Hospital
Investigators
Principal Investigator: Wisit Prasithsirikul, MD Bamrasnaradura infectious disease institute
Principal Investigator: Rawiwan Hansudewechakul, MD Chiangrai Prachanukroh Hospital
Principal Investigator: Wirat Klinbuayam, MD Sanpatong Hospital
Principal Investigator: Jintanat Ananworanich, MD, PhD HIV-NAT, Thai Red Cross - AIDS Research Centre
Principal Investigator: Kulkanya Chokephaibulkit, MD Mahidol University
More Information

Additional Information:
Publications:
Responsible Party: The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier: NCT01328288     History of Changes
Other Study ID Numbers: HIV-NAT 154
First Posted: April 4, 2011    Key Record Dates
Last Update Posted: February 22, 2016
Last Verified: February 2016

Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
HIV related adverse events
Immunological failure
virological failure
quality of life
depression
genotypic resistance

Additional relevant MeSH terms:
Depression
Behavioral Symptoms